首页> Journal of hematology & oncology> CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.

CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.

导出 OA

翻译打印收藏纠错

第一作者： Michele,Stanchina

第一单位： Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

作者： Michele,Stanchina ^[1] ; Alessandro,Pastore ^[1] ; Sean,Devlin ^[2] ; Christopher,Famulare ^[3] ; Eytan,Stein ^[4] ; Justin,Taylor ^[5]

作者单位： Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[1] Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[2] Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[3] Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. ^[4] Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. taylorj7@mskcc.org.;Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. taylorj7@mskcc.org. ^[5]

关键词 Acute myeloid leukemia Antibody-drug conjugate CD33